Paula Williamson

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/2299799/paula-williamson-publications-by-year.pdf
Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

439 papers	25,077 citations	78 h-index	147 g-index
471 ext. papers	30,606 ext. citations	5.3 avg, IF	7.11 L-index

#	Paper	IF	Citations
439	Updating and Integrating Core Outcome Sets for Localised, Locally Advanced, Metastatic, and Nonmetastatic Castration-resistant Prostate Cancer: An Update from the PIONEER Consortium.. *European Urology*, **2022**,	10.2	1
438	Which outcomes should be used in future bronchiolitis trials? Developing a bronchiolitis core outcome set using a systematic review, Delphi survey and a consensus workshop.. *BMJ Open*, **2022**, 12, e052943	3	1
437	Enhancing patient and public contribution in health outcome selection during clinical guideline development: an ethnographic study.. *BMC Health Services Research*, **2022**, 22, 361	2.9	0
436	Opportunities and Challenges for the development of 'Core Outcome Sets' in Neuro-Oncology.. *Neuro-Oncology*, **2022**,	1	1
435	An international Delphi consensus process to determine a common data element and core outcome set for frailty: FOCUS (The Frailty Outcomes Consensus Project).. *BMC Geriatrics*, **2022**, 22, 284	4.1	
434	The British Orthopaedic Surgery Surveillance study: Perthes' disease : the epidemiology and two-year outcomes from a prospective cohort in Great Britain.. *Bone and Joint Journal*, **2022**, 104-B, 510-518	5.6	1
433	The British Orthopaedic Surgery Surveillance study: slipped capital femoral epiphysis : the epidemiology and two-year outcomes from a prospective cohort in Great Britain.. *Bone and Joint Journal*, **2022**, 104-B, 519-528	5.6	2
432	Development of 'Core Outcome Sets' for Meningioma in Clinical Studies (The COSMIC Project): protocol for two systematic literature reviews, eDelphi surveys and online consensus meetings.. *BMJ Open*, **2022**, 12, e057384	3	0
431	A Core Outcome Set for Nonpharmacological Community-Based Interventions for People Living With Dementia at Home: A Systematic Review of Outcome Measurement Instruments. *Gerontologist, The*, **2021**, 61, e435-e448	5	9
430	In-depth qualitative interviews identified barriers and facilitators that influenced chief investigators' use of core outcome sets in randomised controlled trials.. *Journal of Clinical Epidemiology*, **2021**,	5.7	1
429	Patient participation in Delphi surveys to develop core outcome sets: systematic review. *BMJ Open*, **2021**, 11, e051066	3	
428	Outcomes assessed in therapeutic randomised controlled trials in hospitalised patients with COVID-19: is the meta Core outcome set (meta-COS) adopted?. *Clinical Microbiology and Infection*, **2021**,	9.5	0
427	Pan-Stakeholder Core Outcome Set (COS) Definition for Selected Hematological Malignancies - Results of the Harmony Alliance. *Blood*, **2021**, 138, 5031-5031	2.2	
426	Intravenous or oral antibiotic treatment in adults and children with cystic fibrosis and Pseudomonas aeruginosa infection: the TORPEDO-CF RCT. *Health Technology Assessment*, **2021**, 25, 1-128	4.4	1
425	Standardising the Assessment of Patient-reported Outcome Measures in Localised Prostate Cancer. A Systematic Review. *European Urology Oncology*, **2021**,	6.7	2
424	Inclusion of participants from low-income and middle-income countries in core outcome sets development: a systematic review. *BMJ Open*, **2021**, 11, e049981	3	0
423	Developing an online, searchable database to systematically map and organise current literature on retention research (ORRCA2). *Clinical Trials*, **2021**, 17407745211053803	2.2	1

422	A pilot study assessing the uptake of core outcome sets in health technology assessments.. *F1000Research*, **2021**, 10, 1084	3.6	0
421	ERS Statement: A core outcome set for clinical trials evaluating the management of chronic obstructive pulmonary disease (COPD) exacerbations. *European Respiratory Journal*, **2021**,	13.6	5
420	Use of core outcome sets was low in clinical trials published in major medical journals. *Journal of Clinical Epidemiology*, **2021**, 142, 19-28	5.7	1
419	Microdiscectomy compared with transforaminal epidural steroid injection for persistent radicular pain caused by prolapsed intervertebral disc: the NERVES RCT. *Health Technology Assessment*, **2021**, 25, 1-86	4.4	0
418	Does Sleep Position Influence Sleep-Disordered Breathing in Infants With Cleft Palate: A Feasibility Study?. *Cleft Palate-Craniofacial Journal*, **2021**, 10556656211003459	1.9	1
417	The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. *Lancet, The*, **2021**, 397, 1363-1374	40	29
416	The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. *Lancet, The*, **2021**, 397, 1375-1386	40	37
415	Representation of published core outcome sets for research in regulatory guidance: protocol. *HRB Open Research*, **2021**, 4, 45	1.2	1
414	Surgical microdiscectomy versus transforaminal epidural steroid injection in patients with sciatica secondary to herniated lumbar disc (NERVES): a phase 3, multicentre, open-label, randomised controlled trial and economic evaluation. *Lancet Rheumatology, The*, **2021**, 3, e347-e356	14.2	6
413	Methods for conducting international Delphi surveys to optimise global participation in core outcome set development: a case study in gastric cancer informed by a comprehensive literature review. *Trials*, **2021**, 22, 410	2.8	1
412	Realising the full potential of data-enabled trials in the UK: a call for action. *BMJ Open*, **2021**, 11, e043906	3	1
411	Harms reported by patients in rheumatology drug trials: a systematic review of randomized trials in the cochrane library from an OMERACT working group. *Seminars in Arthritis and Rheumatism*, **2021**, 51, 607-617	5.3	1
410	Incidence of sight-threatening diabetic retinopathy in an established urban screening programme: An 11-year cohort study. *Diabetic Medicine*, **2021**, 38, e14583	3.5	0
409	A systematic review finds Core Outcome Set uptake varies widely across different areas of health. *Journal of Clinical Epidemiology*, **2021**, 129, 114-123	5.7	16
408	Core Outcome Measures for Trials in People With Coronavirus Disease 2019: Respiratory Failure, Multiorgan Failure, Shortness of Breath, and Recovery. *Critical Care Medicine*, **2021**, 49, 503-516	1.4	10
407	Document Ranking for Curated Document Databases Using BERT and Knowledge Graph Embeddings: Introducing GRAB-Rank. *Lecture Notes in Computer Science*, **2021**, 116-127	0.9	1
406	Choosing important health outcomes for comparative effectiveness research: 6th annual update to a systematic review of core outcome sets for research. *PLoS ONE*, **2021**, 16, e0244878	3.7	11
405	A randomised controlled trial comparing palate surgery at 6 months versus 12 months of age (the TOPS trial): a statistical analysis plan. *Trials*, **2021**, 22, 5	2.8	1

404	Study protocol to develop a core outcome set for thyroid dysfunction to bridge the unmet needs of patient-centred care. *BMJ Open*, **2021**, 11, e050231	3	0
403	Using routinely recorded data in a UK RCT: a comparison to standard prospective data collection methods. *Trials*, **2021**, 22, 429	2.8	0
402	A strategy to reduce the carbon footprint of clinical trials. *Lancet, The*, **2021**, 398, 281-282	40	2
401	Representation of published core outcome sets for research in regulatory guidance: protocol. *HRB Open Research*, **2021**, 4, 45	1.2	1
400	Patient-reported outcome measures in core outcome sets targeted overlapping domains but through different instruments. *Journal of Clinical Epidemiology*, **2021**, 136, 26-36	5.7	5
399	More than half of systematic reviews have relevant core outcome sets. *Journal of Clinical Epidemiology*, **2021**, 136, 168-179	5.7	9
398	Pirfenidone in heart failure with preserved ejection fraction: a randomized phase 2 trial. *Nature Medicine*, **2021**, 27, 1477-1482	50.5	17
397	An international core outcome set for evaluating interventions to improve informed consent to clinical trials: The ELICIT Study. *Journal of Clinical Epidemiology*, **2021**, 137, 14-22	5.7	1
396	Lung cancer mortality reduction by LDCT screening: UKLS randomised trial results and international meta-analysis. *Lancet Regional Health - Europe, The*, **2021**, 10, 100179		13
395	Patient participation in Delphi surveys to develop core outcome sets: systematic review. *BMJ Open*, **2021**, 11, e051066	3	1
394	How are trial outcomes prioritised by stakeholders from different regions? Analysis of an international Delphi survey to develop a core outcome set in gastric cancer surgery.. *PLoS ONE*, **2021**, 16, e0261937	3.7	0
393	Heterogeneity in outcome assessment for inflammatory bowel disease in routine clinical practice: a mixed-methods study in a sample of English hospitals. *BMJ Open*, **2021**, 11, e056413	3	1
392	Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs.. *Health Technology Assessment*, **2021**, 25, 1-134	4.4	2
391	A survey of knowledge, perceptions and use of core outcome sets among clinical trialists.. *Trials*, **2021**, 22, 937	2.8	2
390	Scout - sarcoidosis outcomes taskforce. A systematic review of outcomes to inform the development of a core outcome set for pulmonary sarcoidosis. *Sarcoidosis Vasculitis and Diffuse Lung Diseases*, **2021**, 38, e2021034	1.1	
389	"Vicarious thinking" was a key driver of score change in Delphi surveys for COS development and is facilitated by feedback of results. *Journal of Clinical Epidemiology*, **2020**, 128, 118-129	5.7	7
388	Methods used in the selection of instruments for outcomes included in core outcome sets have improved since the publication of the COSMIN/COMET guideline. *Journal of Clinical Epidemiology*, **2020**, 125, 64-75	5.7	11
387	Core outcome set measurement for future clinical trials in acute myeloid leukemia: the HARMONY study protocol using a multi-stakeholder consensus-based Delphi process and a final consensus meeting. *Trials*, **2020**, 21, 437	2.8	2

386	Core outcome sets through the healthcare ecosystem: the case of type 2 diabetes mellitus. *Trials*, **2020**, 21, 570	2.8	14
385	What is important to people with dementia living at home? A set of core outcome items for use in the evaluation of non-pharmacological community-based health and social care interventions. *Age and Ageing*, **2020**, 49, 664-671	3	20
384	Therapeutic mammaplasty is a safe and effective alternative to mastectomy with or without immediate breast reconstruction. *British Journal of Surgery*, **2020**, 107, 832-844	5.3	11
383	A scoping review of core outcome sets and their 'mapping' onto real-world data using prostate cancer as a case study. *BMC Medical Research Methodology*, **2020**, 20, 41	4.7	5
382	Where next for inhaled corticosteroids in childhood asthma?. *Lancet Respiratory Medicine,the*, **2020**, 8, 345	35.1	2
381	Core outcome set for the management of acute exacerbations of chronic obstructive pulmonary disease: the COS-AECOPD ERS Task Force study protocol. *ERJ Open Research*, **2020**, 6,	3.5	7
380	Use of routinely collected data in a UK cohort of publicly funded randomised clinical trials. *F1000Research*, **2020**, 9, 323	3.6	4
379	Uptake of core outcome sets by clinical trialists publishing in major medical journals: Protocol. *HRB Open Research*, **2020**, 3, 53	1.2	3
378	Usage Metrics of Web-Based Interventions Evaluated in Randomized Controlled Trials: Systematic Review. *Journal of Medical Internet Research*, **2020**, 22, e15474	7.6	6
377	Methodological Challenges in Web-Based Trials: Update and Insights From the Relatives Education and Coping Toolkit Trial. *JMIR Mental Health*, **2020**, 7, e15878	6	2
376	A web-based, peer-supported self-management intervention to reduce distress in relatives of people with psychosis or bipolar disorder: the REACT RCT. *Health Technology Assessment*, **2020**, 24, 1-142	4.4	6
375	Different corticosteroid induction regimens in children and young people with juvenile idiopathic arthritis: the SIRJIA mixed-methods feasibility study. *Health Technology Assessment*, **2020**, 24, 1-152	4.4	0
374	Open Information Extraction for Knowledge Graph Construction. *Communications in Computer and Information Science*, **2020**, 103-113	0.3	3
373	Maintaining Curated Document Databases Using a Learning to Rank Model: The ORRCA Experience. *Lecture Notes in Computer Science*, **2020**, 345-357	0.9	2
372	Trial Forge Guidance 2: how to decide if a further Study Within A Trial (SWAT) is needed. *Trials*, **2020**, 21, 33	2.8	17
371	Cauda Equina Syndrome Core Outcome Set (CESCOS): An international patient and healthcare professional consensus for research studies. *PLoS ONE*, **2020**, 15, e0225907	3.7	7
370	International Survey to Establish Prioritized Outcomes for Trials in People With Coronavirus Disease 2019. *Critical Care Medicine*, **2020**, 48, 1612-1621	1.4	7
369	Intravenous versus oral antibiotics for eradication of Pseudomonas aeruginosa in cystic fibrosis (TORPEDO-CF): a randomised controlled trial. *Lancet Respiratory Medicine,the*, **2020**, 8, 975-986	35.1	12

368	Standardising definitions for the pre-eclampsia core outcome set: A consensus development study. *Pregnancy Hypertension*, **2020**, 21, 208-217	2.6	4
367	Controversy and Debate Series on Core Outcome Sets. Paper 4: Debate on Paper 1 from the perspective of COMET [Core Outcome Measures in Effectiveness Trials]. *Journal of Clinical Epidemiology*, **2020**, 125, 222-224	5.7	4
366	Core Outcomes Set for Trials in People With Coronavirus Disease 2019. *Critical Care Medicine*, **2020**, 48, 1622-1635	1.4	22
365	Development of an international Core Outcome Set (COS) for best care for the dying person: study protocol. *BMC Palliative Care*, **2020**, 19, 184	3	3
364	A minimal common outcome measure set for COVID-19 clinical research. *Lancet Infectious Diseases, The*, **2020**, 20, e192-e197	25.5	497
363	Assessing the relevance and uptake of core outcome sets (an agreed minimum collection of outcomes to measure in research studies) in Cochrane systematic reviews: a review. *BMJ Open*, **2020**, 10, e036562	3	5
362	Study protocol for a pragmatic randomised controlled trial comparing the effectiveness and cost-effectiveness of levetiracetam and zonisamide versus standard treatments for epilepsy: a comparison of standard and new antiepileptic drugs (SANAD-II). *BMJ Open*, **2020**, 10, e040635	3	4
361	Outcomes Evaluated in Controlled Clinical Trials on the Management of COVID-19: A Methodological Systematic Review. *Life*, **2020**, 10,	3	5
360	Can harmonisation of outcomes bridge the translation gap for pre-clinical research? A systematic review of outcomes measured in mouse models of type 2 diabetes. *Journal of Translational Medicine*, **2020**, 18, 468	8.5	2
359	Use of routinely collected data in a UK cohort of publicly funded randomised clinical trials. *F1000Research*, **2020**, 9, 323	3.6	5
358	TAILoR (TelmisArtan and InsuLin Resistance in Human Immunodeficiency Virus [HIV]): An Adaptive-design, Dose-ranging Phase IIb Randomized Trial of Telmisartan for the Reduction of Insulin Resistance in HIV-positive Individuals on Combination Antiretroviral Therapy. *Clinical Infectious Diseases*, **2020**, 70, 2062-2072	11.6	7
357	Clinical effectiveness of a web-based peer-supported self-management intervention for relatives of people with psychosis or bipolar (REACT): online, observer-blind, randomised controlled superiority trial. *BMC Psychiatry*, **2020**, 20, 160	4.2	7
356	Uptake of core outcome sets by clinical trialists publishing in major medical journals: Protocol. *HRB Open Research*, **2020**, 3, 53	1.2	
355	Cauda Equina Syndrome Core Outcome Set (CESCOS): An international patient and healthcare professional consensus for research studies **2020**, 15, e0225907		
354	Cauda Equina Syndrome Core Outcome Set (CESCOS): An international patient and healthcare professional consensus for research studies **2020**, 15, e0225907		
353	Cauda Equina Syndrome Core Outcome Set (CESCOS): An international patient and healthcare professional consensus for research studies **2020**, 15, e0225907		
352	Cauda Equina Syndrome Core Outcome Set (CESCOS): An international patient and healthcare professional consensus for research studies **2020**, 15, e0225907		
351	Toward a Core Outcome Set for Head, Neck, and Respiratory Disease in Mucopolysaccharidosis Type II: Systematic Literature Review and Assessment of Heterogeneity in Outcome Reporting. *Journal of Inborn Errors of Metabolism and Screening*, **2019**, 7,	0.8	2

350	Assessing the impact of a research funder's recommendation to consider core outcome sets. *PLoS ONE*, **2019**, 14, e0222418	3.7	18
349	A review of current practice in the design and assessment of internal pilots in UK NIHR clinical trials. *Trials*, **2019**, 20, 571	2.8	2
348	Higher number of items associated with significantly lower response rates in COS Delphi surveys. *Journal of Clinical Epidemiology*, **2019**, 108, 110-120	5.7	61
347	Involving people living with dementia in research: an accessible modified Delphi survey for core outcome set development. *Trials*, **2019**, 20, 12	2.8	17
346	Pirfenidone in Heart Failure with Preserved Ejection Fraction-Rationale and Design of the PIROUETTE Trial. *Cardiovascular Drugs and Therapy*, **2019**, 33, 461-470	3.9	31
345	Improvement was needed in the standards of development for cancer core outcome sets. *Journal of Clinical Epidemiology*, **2019**, 112, 36-44	5.7	6
344	Identifying Possible Outcome Domains from Existing Outcome Measures to Inform an OMERACT Core Domain Set for Safety in Rheumatology Trials. *Journal of Rheumatology*, **2019**, 46, 1173-1178	4.1	3
343	Protocol for the development of a core outcome set for cauda equina syndrome: systematic literature review, qualitative interviews, Delphi survey and consensus meeting. *BMJ Open*, **2019**, 9, e024002	2	5
342	Incorporating patients' perspectives into the initial stages of core outcome set development: a rapid review of qualitative studies of type 2 diabetes. *BMJ Open Diabetes Research and Care*, **2019**, 7, e000615	4.5	15
341	Uptake of the OMERACT-OARSI Hip and Knee Osteoarthritis Core Outcome Set: Review of Randomized Controlled Trials from 1997 to 2017. *Journal of Rheumatology*, **2019**, 46, 976-980	4.1	11
340	Improving outcome reporting in clinical trial reports and protocols: study protocol for the Instrument for reporting Planned Endpoints in Clinical Trials (InsPECT). *Trials*, **2019**, 20, 161	2.8	16
339	What is important to people living with dementia?: the 'long-list' of outcome items in the development of a core outcome set for use in the evaluation of non-pharmacological community-based health and social care interventions. *BMC Geriatrics*, **2019**, 19, 94	4.1	27
338	The impact of immediate breast reconstruction on the time to delivery of adjuvant therapy: the iBRA-2 study. *British Journal of Cancer*, **2019**, 120, 883-895	8.7	21
337	Core outcome sets for prevention and treatment of postpartum haemorrhage: an international Delphi consensus study. *BJOG: an International Journal of Obstetrics and Gynaecology*, **2019**, 126, 83-93	3.7	48
336	TREatment of ATopic eczema (TREAT) Registry Taskforce: an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema photo- and systemic therapy registries. *British Journal of Dermatology*, **2019**, 180, 790-801	4	11
335	Industry funding was associated with increased use of core outcome sets. *Journal of Clinical Epidemiology*, **2019**, 115, 90-97	5.7	7
334	Methodological decisions influence the identification of potential core outcomes in studies related to pre-eclampsia: an analysis informing the development of recommendations for future core outcome set developers. *BJOG: an International Journal of Obstetrics and Gynaecology*, **2019**, 126, 1482-1490	3.7	13
333	Evaluation of an automatic article selection method for timelier updates of the Comet Core Outcome Set database. *Database: the Journal of Biological Databases and Curation*, **2019**, 2019,	5	7

332	Patient-reported outcomes **2019**, 479-492		5
331	Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT. *Health Technology Assessment*, **2019**, 23, 1-140	4.4	10
330	Telmisartan to reduce insulin resistance in HIV-positive individuals on combination antiretroviral therapy: the TAILoR dose-ranging Phase II RCT. *Efficacy and Mechanism Evaluation*, **2019**, 6, 1-168	1.7	
329	Core Outcome Set-STAndardised Protocol Items: the COS-STAP Statement. *Trials*, **2019**, 20, 116	2.8	76
328	Selecting Core Outcomes for Randomised Effectiveness trials In Type 2 diabetes (SCORE-IT): a patient and healthcare professional consensus on a core outcome set for type 2 diabetes. *BMJ Open Diabetes Research and Care*, **2019**, 7, e000700	4.5	18
327	Participating in core outcome set development via Delphi surveys: qualitative interviews provide pointers to inform guidance. *BMJ Open*, **2019**, 9, e032338	3	7
326	A Systematic Review of Core Outcomes for Hypospadias Surgery. *Sexual Development*, **2019**, 13, 165-170	1.6	8
325	PPI in research: a reflection from early stage researchers. *Research Involvement and Engagement*, **2019**, 5, 35	4.4	5
324	Choosing important health outcomes for comparative effectiveness research: 5th annual update to a systematic review of core outcome sets for research. *PLoS ONE*, **2019**, 14, e0225980	3.7	48
323	Timing Of Primary Surgery for cleft palate (TOPS): protocol for a randomised trial of palate surgery at 6 months versus 12 months of age. *BMJ Open*, **2019**, 9, e029780	3	19
322	Patient-Focused Drug Development Methods for Benefit-Risk Assessments: A Case Study Using a Discrete Choice Experiment for Antiepileptic Drugs. *Clinical Pharmacology and Therapeutics*, **2019**, 105, 672-683	6.1	13
321	Cost-Effectiveness Analysis of Adalimumab for the Treatment of Uveitis Associated with Juvenile Idiopathic Arthritis. *Ophthalmology*, **2019**, 126, 415-424	7.3	14
320	The OMERACT-OARSI Core Domain Set for Measurement in Clinical Trials of Hip and/or Knee Osteoarthritis. *Journal of Rheumatology*, **2019**, 46, 981-989	4.1	33
319	Short-term safety outcomes of mastectomy and immediate implant-based breast reconstruction with and without mesh (iBRA): a multicentre, prospective cohort study. *Lancet Oncology, The*, **2019**, 20, 254-266	21.7	72
318	Adjustment for treatment changes in epilepsy trials: A comparison of causal methods for time-to-event outcomes. *Statistical Methods in Medical Research*, **2019**, 28, 717-733	2.3	6
317	Model-based sensitivity analysis for outcome reporting bias in the meta analysis of benefit and harm outcomes. *Statistical Methods in Medical Research*, **2019**, 28, 889-903	2.3	11
316	Adherence to best practice consensus guidelines for implant-based breast reconstruction: Results from the iBRA national practice questionnaire survey. *European Journal of Surgical Oncology*, **2018**, 44, 708-716	3.6	10
315	Systematic review of outcome measures following chemoradiotherapy for the treatment of anal cancer (CORMAC). *Colorectal Disease*, **2018**, 20, 371-382	2.1	11

314	Outcomes Reported After Surgery for Cauda Equina Syndrome: A Systematic Literature Review. *Spine*, **2018**, 43, E1005-E1013	3.3	18
313	A taxonomy has been developed for outcomes in medical research to help improve knowledge discovery. *Journal of Clinical Epidemiology*, **2018**, 96, 84-92	5.7	180
312	2017 EULAR recommendations for a core data set to support observational research and clinical care in rheumatoid arthritis. *Annals of the Rheumatic Diseases*, **2018**, 77, 476-479	2.4	45
311	Trial Forge Guidance 1: what is a Study Within A Trial (SWAT)?. *Trials*, **2018**, 19, 139	2.8	94
310	Developing a core outcome set for people living with dementia at home in their neighbourhoods and communities: study protocol for use in the evaluation of non-pharmacological community-based health and social care interventions. *Trials*, **2018**, 19, 247	2.8	21
309	A randomized controlled trial protocol assessing the effectiveness, safety and cost-effectiveness of methotrexate vs. ciclosporin in the treatment of severe atopic eczema in children: the TREatment of severe Atopic eczema Trial (TREAT). *British Journal of Dermatology*, **2018**, 179, 1297-1306	4	8
308	Time-dependent efficacy of longitudinal biomarker for clinical endpoint. *Statistical Methods in Medical Research*, **2018**, 27, 1909-1924	2.3	5
307	iConnect CKD - virtual medical consulting: A web-based chronic kidney disease, hypertension and diabetes integrated care program. *Nephrology*, **2018**, 23, 646-652	2.2	13
306	A framework for prospectively defining progression rules for internal pilot studies monitoring recruitment. *Statistical Methods in Medical Research*, **2018**, 27, 3612-3627	2.3	6
305	A randomized trial comparing three Delphi feedback strategies found no evidence of a difference in a setting with high initial agreement. *Journal of Clinical Epidemiology*, **2018**, 93, 1-8	5.7	26
304	Inadequate safety reporting in pre-eclampsia trials: a systematic evaluation. *BJOG: an International Journal of Obstetrics and Gynaecology*, **2018**, 125, 795-803	3.7	22
303	Physical Rehabilitation Core Outcomes In Critical illness (PRACTICE): protocol for development of a core outcome set. *Trials*, **2018**, 19, 294	2.8	22
302	Identifying trial recruitment uncertainties using a James Lind Alliance Priority Setting Partnership - the PRioRiTy (Prioritising Recruitment in Randomised Trials) study. *Trials*, **2018**, 19, 147	2.8	54
301	Global health trials methodological research agenda: results from a priority setting exercise. *Trials*, **2018**, 19, 48	2.8	21
300	Survey indicated that core outcome set development is increasingly including patients, being conducted internationally and using Delphi surveys. *Trials*, **2018**, 19, 113	2.8	30
299	Quality Measurement Recommendations Relevant to Clinical Guidelines in Germany and the United Kingdom: (What) Can We Learn From Each Other?. *Inquiry (United States)*, **2018**, 55, 46958018761495	1.4	5
298	Choosing important health outcomes for comparative effectiveness research: An updated systematic review and involvement of low and middle income countries. *PLoS ONE*, **2018**, 13, e0190695	3.7	36
297	Development of a consensus core dataset in juvenile dermatomyositis for clinical use to inform research. *Annals of the Rheumatic Diseases*, **2018**, 77, 241-250	2.4	20

296	Choosing important health outcomes for comparative effectiveness research: 4th annual update to a systematic review of core outcome sets for research. *PLoS ONE*, **2018**, 13, e0209869	3.7	39
295	Interventions for helping people recognise early signs of recurrence in depression. *The Cochrane Library*, **2018**,	5.2	78
294	Non-invasive ventilation for the management of children with bronchiolitis (NOVEMBR): a feasibility study and core outcome set development protocol. *Trials*, **2018**, 19, 627	2.8	6
293	A core outcome set for clinical trials of chemoradiotherapy interventions for anal cancer (CORMAC): a patient and health-care professional consensus. *The Lancet Gastroenterology and Hepatology*, **2018**, 3, 865-873	18.8	35
292	Reducing attrition within clinical trials: The communication of retention and withdrawal within patient information leaflets. *PLoS ONE*, **2018**, 13, e0204886	3.7	14
291	Outcome reporting bias in trials: a methodological approach for assessment and adjustment in systematic reviews. *BMJ, The*, **2018**, 362, k3802	5.9	52
290	Development of a standardised set of metrics for monitoring site performance in multicentre randomised trials: a Delphi study. *Trials*, **2018**, 19, 557	2.8	10
289	Reporting of outcomes in gastric cancer surgery trials: a systematic review. *BMJ Open*, **2018**, 8, e021796	3	14
288	Nerve root block versus surgery (NERVES) for the treatment of radicular pain secondary to a prolapsed intervertebral disc herniation: study protocol for a multi-centre randomised controlled trial. *Trials*, **2018**, 19, 475	2.8	4
287	Development of an online resource for recruitment research in clinical trials to organise and map current literature. *Clinical Trials*, **2018**, 15, 533-542	2.2	29
286	Selecting Core Outcomes for Randomised Effectiveness trials In Type 2 Diabetes (SCORE-IT): study protocol for the development of a core outcome set. *Trials*, **2018**, 19, 427	2.8	6
285	Clinical trials and systematic reviews addressing similar interventions for the same condition do not consider similar outcomes to be important: a case study in HIV/AIDS. *Journal of Clinical Epidemiology*, **2017**, 84, 85-94	5.7	21
284	TREatment of ATopic eczema (TREAT) Registry Taskforce: protocol for an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema registries. *Trials*, **2017**, 18, 87	2.8	14
283	Core outcome sets in women's and newborn health: a systematic review. *BJOG: an International Journal of Obstetrics and Gynaecology*, **2017**, 124, 1481-1489	3.7	99
282	Outcome reporting across randomised controlled trials evaluating therapeutic interventions for pre-eclampsia. *BJOG: an International Journal of Obstetrics and Gynaecology*, **2017**, 124, 1829-1839	3.7	30
281	Improving core outcome set development: qualitative interviews with developers provided pointers to inform guidance. *Journal of Clinical Epidemiology*, **2017**, 86, 140-152	5.7	28
280	Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis. *New England Journal of Medicine*, **2017**, 376, 1637-1646	59.2	218
279	Priorities for methodological research on patient and public involvement in clinical trials: A modified Delphi process. *Health Expectations*, **2017**, 20, 1401-1410	3.7	29

278	Citation analysis did not provide a reliable assessment of core outcome set uptake. *Journal of Clinical Epidemiology*, **2017**, 86, 153-159	5.7	12
277	A core outcome set for localised prostate cancer effectiveness trials. *BJU International*, **2017**, 120, E64-E70	3.9	34
276	Resource implications of preparing individual participant data from a clinical trial to share with external researchers. *Trials*, **2017**, 18, 319	2.8	12
275	Standardising the reporting of outcomes in gastric cancer surgery trials: protocol for the development of a core outcome set and accompanying outcome measurement instrument set (the GASTROS study). *Trials*, **2017**, 18, 370	2.8	17
274	Identifying research priorities for effective retention strategies in clinical trials. *Trials*, **2017**, 18, 406	2.8	23
273	Using routinely recorded data in the UK to assess outcomes in a randomised controlled trial: The Trials of Access. *Trials*, **2017**, 18, 389	2.8	10
272	A framework for the design, conduct and interpretation of randomised controlled trials in the presence of treatment changes. *Trials*, **2017**, 18, 498	2.8	16
271	SCORE-IT (Selecting Core Outcomes for Randomised Effectiveness trials In Type 2 diabetes): a systematic review of registered trials. *Trials*, **2017**, 18, 597	2.8	10
270	Core Health Outcomes In Childhood Epilepsy (CHOICE): protocol for the selection of a core outcome set. *Trials*, **2017**, 18, 572	2.8	9
269	Do systematic reviews still exclude studies with "no relevant outcome data"?. *BMJ, The*, **2017**, 358, j3919	5.9	3
268	Protocol for an online randomised controlled trial to evaluate the clinical and cost-effectiveness of a peer-supported self-management intervention for relatives of people with psychosis or bipolar disorder: Relatives Education And Coping Toolkit (REACT). *BMJ Open*, **2017**, 7, e016965	3	16
267	Variation in the provision and practice of implant-based breast reconstruction in the UK: Results from the iBRA national practice questionnaire. *Breast*, **2017**, 35, 182-190	3.6	17
266	Exploring the utility of grids for analysing long term population change. *Computers, Environment and Urban Systems*, **2017**, 66, 1-12	5.9	18
265	A systematic review of primary outcomes and outcome measure reporting in randomized trials evaluating treatments for pre-eclampsia. *International Journal of Gynecology and Obstetrics*, **2017**, 139, 262-267	4	24
264	The COMET Initiative database: progress and activities update (2015). *Trials*, **2017**, 18, 54	2.8	27
263	The COMET Handbook: version 1.0. *Trials*, **2017**, 18, 280	2.8	663
262	Core outcome research measures in anal cancer. *Colorectal Disease*, **2017**, 19, 782-783	2.1	
261	Informing efficient randomised controlled trials: exploration of challenges in developing progression criteria for internal pilot studies. *BMJ Open*, **2017**, 7, e013537	3	122

260	Developing an OMERACT Core Outcome Set for Assessing Safety Components in Rheumatology Trials: The OMERACT Safety Working Group. *Journal of Rheumatology*, **2017**, 44, 1916-1919	4.1	10
259	Guidelines for the Content of Statistical Analysis Plans in Clinical Trials. *JAMA - Journal of the American Medical Association*, **2017**, 318, 2337-2343	27.4	159
258	A methodological approach for assessing the uptake of core outcome sets using ClinicalTrials.gov: findings from a review of randomised controlled trials of rheumatoid arthritis. *BMJ, The*, **2017**, 357, j2262	5.9	54
257	Core outcome research measures in anal cancer (CORMAC): protocol for systematic review, qualitative interviews and Delphi survey to develop a core outcome set in anal cancer. *BMJ Open*, **2017**, 7, e018726	3	13
256	PO240 Using routinely recorded data in a clinical trial. *Journal of Neurology, Neurosurgery and Psychiatry*, **2017**, 88, A75.3-A75	5.5	
255	Core Outcome Set-STAndards for Development: The COS-STAD recommendations. *PLoS Medicine*, **2017**, 14, e1002447	11.6	242
254	Duration of intravenous antibiotic therapy for children with acute osteomyelitis or septic arthritis: a feasibility study. *Health Technology Assessment*, **2017**, 21, 1-164	4.4	11
253	UK publicly funded Clinical Trials Units supported a controlled access approach to share individual participant data but highlighted concerns. *Journal of Clinical Epidemiology*, **2016**, 70, 17-25	5.7	33
252	Development of a core outcome set for clinical trials in rosacea: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey. *Trials*, **2016**, 17, 429	2.8	19
251	Feasibility study to examine discrepancy rates in prespecified and reported outcomes in articles submitted to The BMJ. *BMJ Open*, **2016**, 6, e010075	3	6
250	The iBRA (implant breast reconstruction evaluation) study: protocol for a prospective multi-centre cohort study to inform the feasibility, design and conduct of a pragmatic randomised clinical trial comparing new techniques of implant-based breast reconstruction. *Pilot and Feasibility Studies*, **2016**, 2, 41	1.9	22
249	Assessing the feasibility of injectable growth-promoting therapy in Crohn's disease. *Pilot and Feasibility Studies*, **2016**, 2, 71	1.9	2
248	Core outcome sets and systematic reviews. *Systematic Reviews*, **2016**, 5, 11	3	91
247	The use of qualitative methods to inform Delphi surveys in core outcome set development. *Trials*, **2016**, 17, 230	2.8	63
246	A patient and public involvement (PPI) toolkit for meaningful and flexible involvement in clinical trials - a work in progress. *Research Involvement and Engagement*, **2016**, 2, 15	4.4	83
245	Modelling variable dropout in randomised controlled trials with longitudinal outcomes: application to the MAGNETIC study. *Trials*, **2016**, 17, 222	2.8	5
244	TO THE EDITOR. *Spine*, **2016**, 41, E301-2	3.3	
243	A multi-factorial analysis of response to warfarin in a UK prospective cohort. *Genome Medicine*, **2016**, 8, 2	14.4	32

242	UK Lung Cancer RCT Pilot Screening Trial: baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening. *Thorax*, **2016**, 71, 161-70	7.3	163
241	Core Outcome Set-STAndards for Reporting: The COS-STAR Statement. *PLoS Medicine*, **2016**, 13, e1002148	4.6	251
240	Choosing Important Health Outcomes for Comparative Effectiveness Research: An Updated Review and User Survey. *PLoS ONE*, **2016**, 11, e0146444	3.7	91
239	How Much Participant Outcome Data Is Missing from Sight: Findings from a Cohort of Trials Submitted to a German Research Ethics Committee. *PLoS ONE*, **2016**, 11, e0157883	3.7	1
238	The UK Lung Cancer Screening Trial: a pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer. *Health Technology Assessment*, **2016**, 20, 1-146	4.4	124
237	Three nested randomized controlled trials of peer-only or multiple stakeholder group feedback within Delphi surveys during core outcome and information set development. *Trials*, **2016**, 17, 409	2.8	52
236	Choosing Important Health Outcomes for Comparative Effectiveness Research: An Updated Review and Identification of Gaps. *PLoS ONE*, **2016**, 11, e0168403	3.7	49
235	A Core Outcome Set for Evaluation of Interventions to Prevent Preterm Birth. *Obstetrics and Gynecology*, **2016**, 127, 49-58	4.9	124
234	A core outcome set for neonatal abstinence syndrome: study protocol for a systematic review, parent interviews and a Delphi survey. *Trials*, **2016**, 17, 536	2.8	23
233	The iBRA-2 (immediate breast reconstruction and adjuvant therapy audit) study: protocol for a prospective national multicentre cohort study to evaluate the impact of immediate breast reconstruction on the delivery of adjuvant therapy. *BMJ Open*, **2016**, 6, e012678	3	7
232	A survey of facilitators and barriers to recruitment to the MAGNETIC trial. *Trials*, **2016**, 17, 607	2.8	13
231	How to select outcome measurement instruments for outcomes included in a "Core Outcome Set" - a practical guideline. *Trials*, **2016**, 17, 449	2.8	420
230	Improving the relevance and consistency of outcomes in comparative effectiveness research. *Journal of Comparative Effectiveness Research*, **2016**, 5, 193-205	2.1	51
229	A protocol for developing, disseminating, and implementing a core outcome set for pre-eclampsia. *Pregnancy Hypertension*, **2016**, 6, 274-278	2.6	43
228	A Randomized Controlled Trial of Extended Brief Intervention for Alcohol-Dependent Patients in an Acute Hospital Setting. *Alcohol and Alcoholism*, **2016**, 51, 584-92	3.5	1
227	Individual participant data meta-analyses compared with meta-analyses based on aggregate data. *The Cochrane Library*, **2016**, 9, MR000007	5.2	41
226	Questioning assent: how are children's views included as families make decisions about clinical trials?. *Child: Care, Health and Development*, **2016**, 42, 900-908	2.8	12
225	Survey of new 2007 and 2011 Cochrane reviews found 37% of prespecified outcomes not reported. *Journal of Clinical Epidemiology*, **2015**, 68, 237-45	5.7	28

224	RE: Recommended patient-reported core set of symptoms to measure in adult cancer treatment trials. *Journal of the National Cancer Institute*, **2015**, 107,	9.7	2
223	Multivariate meta-analysis helps examine the impact of outcome reporting bias in Cochrane rheumatoid arthritis reviews. *Journal of Clinical Epidemiology*, **2015**, 68, 542-50	5.7	12
222	Collating the knowledge base for core outcome set development: developing and appraising the search strategy for a systematic review. *BMC Medical Research Methodology*, **2015**, 15, 26	4.7	21
221	Core outcome sets for use in effectiveness trials involving people with bipolar and schizophrenia in a community-based setting (PARTNERS2): study protocol for the development of two core outcome sets. *Trials*, **2015**, 16, 47	2.8	16
220	Consensus on the Need for a Hierarchical List of Patient-reported Pain Outcomes for Metaanalyses of Knee Osteoarthritis Trials: An OMERACT Objective. *Journal of Rheumatology*, **2015**, 42, 1971-1975	4.1	14
219	Prokinetics prescribing in paediatrics: evidence on cisapride, domperidone, and metoclopramide. *Journal of Pediatric Gastroenterology and Nutrition*, **2015**, 60, 508-14	2.8	16
218	Dialogue on Developing Consensus on Measurement and Presentation of Patient-important Outcomes, Using Pain Outcomes as an Exemplar, in Systematic Reviews: A Preconference Meeting at OMERACT 12. *Journal of Rheumatology*, **2015**, 42, 1931-1933	4.1	8
217	A pilot randomised controlled trial to assess the utility of an e-learning package that trains users in adverse drug reaction causality. *International Journal of Pharmacy Practice*, **2015**, 23, 447-55	1.7	9
216	Good practice principles for sharing individual participant data from publicly funded clinical trials. *Trials*, **2015**, 16,	2.8	19
215	Citation analysis: a new approach to assess the uptake of core outcome sets. *Trials*, **2015**, 16,	2.8	1
214	Telmisartan and Insulin Resistance in HIV (TAILoR): protocol for a dose-ranging phase II randomised open-labelled trial of telmisartan as a strategy for the reduction of insulin resistance in HIV-positive individuals on combination antiretroviral therapy. *BMJ Open*, **2015**, 5, e009566	3	8
213	PARTNERS2: a protocol for the development of a core outcome set for use in mental health trials involving people with schizophrenia or bipolar disorder in a community setting. *Trials*, **2015**, 16,	2.8	78
212	A survey of core outcome set developers. *Trials*, **2015**, 16,	2.8	78
211	Choosing important health outcomes for comparative effectiveness research: an updated review and user survey. *Trials*, **2015**, 16,	2.8	78
210	Re: Neil E. Martin, Laura Massey, Caleb Stowell, et al. Defining a Standard Set of Patient-centered Outcomes for Men with Localized Prostate Cancer. Eur Urol 2015;67:460-7. *European Urology*, **2015**, 68, e123-4	10.2	5
209	COS-STAR: a reporting guideline for studies developing core outcome sets (protocol). *Trials*, **2015**, 16, 373	2.8	44
208	The COMET initiative database: progress and activities update (2014). *Trials*, **2015**, 16, 515	2.8	28
207	A little more conversation please? Qualitative study of researchers' and patients' interview accounts of training for patient and public involvement in clinical trials. *Trials*, **2015**, 16, 190	2.8	58

206	Evaluation of interventions for informed consent for randomised controlled trials (ELICIT): protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey. *Trials*, **2015**, 16, 484	2.8	17
205	How should individual participant data (IPD) from publicly funded clinical trials be shared?. *BMC Medicine*, **2015**, 13, 298	11.4	36
204	The natural history of conducting and reporting clinical trials: interviews with trialists. *Trials*, **2015**, 16, 16	2.8	18
203	Core outcome sets and trial registries. *Trials*, **2015**, 16, 216	2.8	30
202	Development of an internationally agreed minimal dataset for juvenile dermatomyositis (JDM) for clinical and research use. *Trials*, **2015**, 16, 268	2.8	15
201	Core Outcomes in Ventilation Trials (COVenT): protocol for a core outcome set using a Delphi survey with a nested randomised trial and observational cohort study. *Trials*, **2015**, 16, 368	2.8	41
200	Towards core outcome set (COS) development: a follow-up descriptive survey of outcomes in Cochrane reviews. *Systematic Reviews*, **2015**, 4, 73	3	16
199	Consensus on the need for a hierarchical list of patient-reported pain outcomes for meta-analyses of knee osteoarthritis trials. *Trials*, **2015**, 16,	2.8	78
198	Using qualitative research to understand what outcomes matter to patients: direct and indirect approaches to outcome elicitation. *Trials*, **2015**, 16,	2.8	2
197	Development and evaluation of an electronic diary for recording patient reported outcomes in the overt study. *Trials*, **2015**, 16,	2.8	78
196	Developing a toolkit for patient and public involvement in a clinical trials unit. *Trials*, **2015**, 16,	2.8	78
195	Optimising the design of internal pilot work to inform efficient randomised controlled trials: issues to consider when developing progression criteria. *Trials*, **2015**, 16,	2.8	2
194	Reported reasons for missing data and the interplay with trial setting. *Trials*, **2015**, 16,	2.8	78
193	To have, to hold, from this day forward: understanding current practice regarding the retention of trial participants. *Trials*, **2015**, 16,	2.8	78
192	The trials and tribulations of accessing data from routine sources. *Trials*, **2015**, 16,	2.8	78
191	Pragmatic approaches to mitigating missing data and research priorities to assess the effectiveness of interventions. *Trials*, **2015**, 16,	2.8	78
190	A review of the description of patient withdrawal in trial protocols and patient information sheets (PIS). *Trials*, **2015**, 16,	2.8	78
189	Three nested RCTs of dual or single stakeholder feedback within Delphi surveys during core outcome and information set development. *Trials*, **2015**, 16,	2.8	78

188	Evaluation of interventions for informed consent for randomised controlled trials (ELICIT): developing a core outcome set. *Trials*, **2015**, 16,	2.8	78
187	A mixed methods study of researchers experiences of developing core outcome sets. *Trials*, **2015**, 16,	2.8	78
186	The core outcome measures in effectiveness trials (COMET) initiative: five years on. *Trials*, **2015**, 16,	2.8	3
185	Development of an online resource for recruitment research in clinical trials (ORRCA). *Trials*, **2015**, 16,	2.8	4
184	A core outcome set for localised prostate cancer effectiveness trials: protocol for a systematic review of the literature and stakeholder involvement through interviews and a Delphi survey. *Trials* , **2015**, 16, 76	2.8	40
183	What Difference Does Patient and Public Involvement Make and What Are Its Pathways to Impact? Qualitative Study of Patients and Researchers from a Cohort of Randomised Clinical Trials. *PLoS ONE*, **2015**, 10, e0128817	3.7	70
182	The Importance of Integration of Stakeholder Views in Core Outcome Set Development: Otitis Media with Effusion in Children with Cleft Palate. *PLoS ONE*, **2015**, 10, e0129514	3.7	70
181	An evidence base to optimise methods for involving patient and public contributors in clinical trials: a mixed-methods study. *Health Services and Delivery Research*, **2015**, 3, 1-142	1.5	17
180	The management of Otitis Media with Effusion in children with cleft palate (mOMEnt): a feasibility study and economic evaluation. *Health Technology Assessment*, **2015**, 19, 1-374	4.4	34
179	The trials methodological research agenda: results from a priority setting exercise. *Trials*, **2014**, 15, 32	2.8	98
178	Core outcome sets will improve the quality of obstetrics research. *BJOG: an International Journal of Obstetrics and Gynaecology*, **2014**, 121, 1196-1196	3.7	2
177	Amnioinfusion in very early preterm prelabor rupture of membranes (AMIPROM): pregnancy, neonatal and maternal outcomes in a randomized controlled pilot study. *Ultrasound in Obstetrics and Gynecology*, **2014**, 43, 490-9	5.8	16
176	A review of the handling of missing longitudinal outcome data in clinical trials. *Trials*, **2014**, 15, 237	2.8	45
175	The COMET Initiative database: progress and activities from 2011 to 2013. *Trials*, **2014**, 15, 279	2.8	72
174	Risk-proportionate clinical trial monitoring: an example approach from a non-commercial trials unit. *Trials*, **2014**, 15, 127	2.8	13
173	A model-based correction for outcome reporting bias in meta-analysis. *Biostatistics*, **2014**, 15, 370-83	3.7	23
172	Sharing individual participant data from clinical trials: an opinion survey regarding the establishment of a central repository. *PLoS ONE*, **2014**, 9, e97886	3.7	31
171	Choosing important health outcomes for comparative effectiveness research: a systematic review. *PLoS ONE*, **2014**, 9, e99111	3.7	193

170	Interventions to improve recruitment and retention in clinical trials: a survey and workshop to assess current practice and future priorities. *Trials*, **2014**, 15, 399	2.8	221
169	Economic evaluation of nebulized magnesium sulphate in acute severe asthma in children. *International Journal of Technology Assessment in Health Care*, **2014**, 30, 354-60	1.8	6
168	Time to 12-month remission and treatment failure for generalised and unclassified epilepsy. *Journal of Neurology, Neurosurgery and Psychiatry*, **2014**, 85, 603-10	5.5	38
167	Evidence for the selective reporting of analyses and discrepancies in clinical trials: a systematic review of cohort studies of clinical trials. *PLoS Medicine*, **2014**, 11, e1001666	11.6	106
166	Patient and public involvement in the early stages of clinical trial development: a systematic cohort investigation. *BMJ Open*, **2014**, 4, e005234	3	37
165	Opening research sites in multicentre clinical trials within the UK: a detailed analysis of delays. *BMJ Open*, **2014**, 4, e005874	3	17
164	From plans to actions in patient and public involvement: qualitative study of documented plans and the accounts of researchers and patients sampled from a cohort of clinical trials. *BMJ Open*, **2014**, 4, e006400	3	63
163	Selective reporting bias of harm outcomes within studies: findings from a cohort of systematic reviews. *BMJ, The*, **2014**, 349, g6501	5.9	110
162	Methodology of clinical trials for rare diseases. *Best Practice and Research in Clinical Rheumatology*, **2014**, 28, 247-62	5.3	26
161	Statistical power of multilevel modelling in dental caries clinical trials: a simulation study. *Caries Research*, **2014**, 48, 13-8	4.2	4
160	The UK Lung Screen (UKLS): demographic profile of first 88,897 approaches provides recommendations for population screening. *Cancer Prevention Research*, **2014**, 7, 362-71	3.2	84
159	Amnioinfusion in preterm premature rupture of membranes (AMIPROM): a randomised controlled trial of amnioinfusion versus expectant management in very early preterm premature rupture of membranes--a pilot study. *Health Technology Assessment*, **2014**, 18, 1-135	4.4	14
158	ADRIC: Adverse Drug Reactions In Children – a programme of research using mixed methods. *Programme Grants for Applied Research*, **2014**, 2, 1-184	1.5	8
157	MOMENT--Management of Otitis Media with Effusion in Cleft Palate: protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey. *Trials*, **2013**, 14, 70	2.8	127
156	Can a core outcome set improve the quality of systematic reviews?--a survey of the Co-ordinating Editors of Cochrane Review Groups. *Trials*, **2013**, 14, 21	2.8	113
155	The use of systematic reviews in the planning, design and conduct of randomised trials: a retrospective cohort of NIHR HTA funded trials. *BMC Medical Research Methodology*, **2013**, 13, 50	4.7	47
154	A randomized trial of genotype-guided dosing of warfarin. *New England Journal of Medicine*, **2013**, 369, 2294-303	59.2	617
153	Outcome measures in rheumatoid arthritis randomised trials over the last 50 years. *Trials*, **2013**, 14, 324	2.8	113

152	A multistate modelling approach for pancreatic cancer development in genetically high-risk families. *Journal of the Royal Statistical Society Series C: Applied Statistics*, **2013**, 62, 201-212	1.5	2
151	Magnesium sulphate in acute severe asthma in children (MAGNETIC): a randomised, placebo-controlled trial. *Lancet Respiratory Medicine,the*, **2013**, 1, 301-8	35.1	54
150	Barriers to recruitment for surgical trials in head and neck oncology: a survey of trial investigators. *BMJ Open*, **2013**, 3,	3	41
149	A survey of facilitators and barriers to recruitment to the magnetic trial. *Trials*, **2013**, 14,	2.8	78
148	Design considerations in the development of a core outcome set. *Trials*, **2013**, 14,	2.8	78
147	Core outcome set development: the effect of Delphi panel composition and feedback on prioritisation of outcomes. *Trials*, **2013**, 14,	2.8	10
146	Incidence, characteristics and risk factors of adverse drug reactions in hospitalized children - a prospective observational cohort study of 6,601 admissions. *BMC Medicine*, **2013**, 11, 237	11.4	54
145	Combining individual patient data and aggregate data in mixed treatment comparison meta-analysis: Individual patient data may be beneficial if only for a subset of trials. *Statistics in Medicine*, **2013**, 32, 914-30	2.3	53
144	Selective reporting of outcomes in randomised controlled trials in systematic reviews of cystic fibrosis. *BMJ Open*, **2013**, 3,	3	26
143	Adherence and variability in warfarin dose requirements: assessment in a prospective cohort. *Pharmacogenomics*, **2013**, 14, 151-63	2.6	12
142	Authors' response. *Thorax*, **2013**, 68, 105	7.3	
141	Assessing key assumptions of network meta-analysis: a review of methods. *Research Synthesis Methods*, **2013**, 4, 291-323	7.2	136
140	New European Union regulation of clinical trials is conflicting on deferred consent in emergency situations. *BMJ, The*, **2013**, 346, f667	5.9	7
139	The role of systematic reviews in pharmacovigilance planning and Clinical Trials Authorisation application: example from the SLEEPS trial. *PLoS ONE*, **2013**, 8, e51787	3.7	5
138	Parents' agendas in paediatric clinical trial recruitment are different from researchers' and often remain unvoiced: a qualitative study. *PLoS ONE*, **2013**, 8, e67352	3.7	44
137	Systematic review of the empirical evidence of study publication bias and outcome reporting bias - an updated review. *PLoS ONE*, **2013**, 8, e66844	3.7	585
136	Management of Asthma in School age Children On Therapy (MASCOT): a randomised, double-blind, placebo-controlled, parallel study of efficacy and safety. *Health Technology Assessment*, **2013**, 17, 1-218	4.4	20
135	Prognostic factors for time to treatment failure and time to 12 months of remission for patients with focal epilepsy: post-hoc, subgroup analyses of data from the SANAD trial. *Lancet Neurology, The*, **2012**, 11, 331-40	24.1	48

134	Melatonin for sleep problems in children with neurodevelopmental disorders: randomised double masked placebo controlled trial. *BMJ, The*, **2012**, 345, e6664	5.9	120
133	Development of a core outcome set for clinical trials in childhood asthma: a survey of clinicians, parents, and young people. *Trials*, **2012**, 13, 103	2.8	108
132	Developing core outcome sets for clinical trials: issues to consider. *Trials*, **2012**, 13, 132	2.8	861
131	Nonadherence to treatment protocol in published randomised controlled trials: a review. *Trials*, **2012**, 13, 84	2.8	54
130	Developing a survey of barriers and facilitators to recruitment in randomized controlled trials. *Trials*, **2012**, 13, 218	2.8	47
129	What parents of children who have received emergency care think about deferring consent in randomised trials of emergency treatments: postal survey. *PLoS ONE*, **2012**, 7, e35982	3.7	36
128	Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis. *PLoS ONE*, **2012**, 7, e44064	3.7	113
127	The COMET (Core Outcome Measures in Effectiveness Trials) Initiative: Its Role in Improving Cochrane Reviews. *Cochrane Database of Systematic Reviews*, **2012**, ED000041		67
126	A multivariate meta-analysis approach for reducing the impact of outcome reporting bias in systematic reviews. *Statistics in Medicine*, **2012**, 31, 2179-95	2.3	63
125	Assessing the consistency assumption by exploring treatment by covariate interactions in mixed treatment comparison meta-analysis: individual patient-level covariates versus aggregate trial-level covariates. *Statistics in Medicine*, **2012**, 31, 3840-57	2.3	34
124	Standard 5: selection, measurement, and reporting of outcomes in clinical trials in children. *Pediatrics*, **2012**, 129 Suppl 3, S146-52	7.4	58
123	The use of MElatonin in children with neurodevelopmental disorders and impaired sleep: a randomised, double-blind, placebo-controlled, parallel study (MENDS). *Health Technology Assessment*, **2012**, 16, i-239	4.4	48
122	Adverse drug reactions in children--a systematic review. *PLoS ONE*, **2012**, 7, e24061	3.7	154
121	Adverse drug reactions causing admission to a paediatric hospital. *PLoS ONE*, **2012**, 7, e50127	3.7	49
120	Comparison of protocols and registry entries to published reports for randomised controlled trials. *The Cochrane Library*, **2011**, MR000031	5.2	128
119	Development and inter-rater reliability of the Liverpool adverse drug reaction causality assessment tool. *PLoS ONE*, **2011**, 6, e28096	3.7	110
118	Adverse drug reactions causing admission to a paediatric hospital: a pilot study. *Journal of Clinical Pharmacy and Therapeutics*, **2011**, 36, 194-9	2.2	21
117	Reporting of adverse events in randomised controlled trials of antiepileptic drugs using the CONSORT criteria for reporting harms. *Epilepsy Research*, **2011**, 97, 20-9	3	29

116	A randomised controlled trial of extended brief intervention for alcohol dependent patients in an acute hospital setting (ADPAC). *BMC Public Health*, **2011**, 11, 528	4.1	8
115	What parents think about being approached about children's trials, how this differs from what practitioners expect, and what this tells us about enhancing recruitment. *Trials*, **2011**, 12,	2.8	3
114	Individual participant data meta-analyses compared with meta-analyses based on aggregate data. *Trials*, **2011**, 12,	2.8	4
113	The COMET (Core Outcome Measures in Effectiveness Trials) Initiative. *Trials*, **2011**, 12,	2.8	65
112	Frequency and reasons for outcome reporting bias in clinical trials: interviews with trialists. *BMJ, The*, **2011**, 342, c7153	5.9	121
111	Seizure recurrence after antiepileptic drug withdrawal and the implications for driving: further results from the MRC Antiepileptic Drug Withdrawal Study and a systematic review. *Journal of Neurology, Neurosurgery and Psychiatry*, **2011**, 82, 1328-33	5.5	39
110	CT screening for lung cancer in the UK: position statement by UKLS investigators following the NLST report. *Thorax*, **2011**, 66, 736-7	7.3	25
109	Using the Delphi technique to determine which outcomes to measure in clinical trials: recommendations for the future based on a systematic review of existing studies. *PLoS Medicine*, **2011**, 8, e1000393	11.6	470
108	A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial. *PLoS Medicine*, **2011**, 8, e1001119	11.6	114
107	Communication about children's clinical trials as observed and experienced: qualitative study of parents and practitioners. *PLoS ONE*, **2011**, 6, e21604	3.7	51
106	Processes in recruitment to randomised controlled trials of medicines for children (RECRUIT): a qualitative study. *Health Technology Assessment*, **2011**, 15, 1-116	4.4	54
105	Comparison of protocols and registry entries to published reports for randomised controlled trials **2010**,		1
104	Bias due to changes in specified outcomes during the systematic review process. *PLoS ONE*, **2010**, 5, e9810	3.7	96
103	Indirect comparisons: a review of reporting and methodological quality. *PLoS ONE*, **2010**, 5, e11054	3.7	93
102	The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. *BMJ, The*, **2010**, 340, c365	5.9	697
101	Risk of recurrence after a first seizure and implications for driving: further analysis of the Multicentre study of early Epilepsy and Single Seizures. *BMJ, The*, **2010**, 341, c6477	5.9	35
100	Feasibility study to inform the design of a randomised controlled trial to eradicate Pseudomonas aeruginosa infection in individuals with cystic fibrosis. *Trials*, **2010**, 11, 11	2.8	8
99	Assessing the potential for outcome reporting bias in a review: a tutorial. *Trials*, **2010**, 11, 52	2.8	44

98	Outcomes in clinical trials of inhaled corticosteroids for children with asthma are narrowly focussed on short term disease activity. *PLoS ONE*, **2009**, 4, e6276	3.7	39
97	Meta-analysis of individual patient data versus aggregate data from longitudinal clinical trials. *Clinical Trials*, **2009**, 6, 16-27	2.2	108
96	Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study. *Pharmacogenetics and Genomics*, **2009**, 19, 800-12	1.9	49
95	Effects of CYP4F2 genetic polymorphisms and haplotypes on clinical outcomes in patients initiated on warfarin therapy. *Pharmacogenetics and Genomics*, **2009**, 19, 781-9	1.9	46
94	Interpreting regulatory trials in epilepsy. *Current Opinion in Neurology*, **2009**, 22, 167-73	7.1	18
93	Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. *PLoS ONE*, **2009**, 4, e4439	3.7	416
92	Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. *Clinical Pharmacology and Therapeutics*, **2008**, 83, 258-64	6.1	231
91	Author response to: Cervical stitch (cerclage) for preventing pregnancy loss: individual patient data meta-analysis. *BJOG: an International Journal of Obstetrics and Gynaecology*, **2008**, 115, 798-799	3.7	
90	Modelling the bilateral symmetry of caries incidence. *Caries Research*, **2008**, 42, 291-6	4.2	14
89	A randomized controlled clinical trial of 2295 ultrasound-guided embryo transfers. *Human Reproduction*, **2008**, 23, 1101-6	5.7	26
88	Two-year placebo-controlled trial of botulinum toxin A for leg spasticity in cerebral palsy. *Neurology*, **2008**, 71, 122-8	6.5	42
87	A systematic review of studies that aim to determine which outcomes to measure in clinical trials in children. *PLoS Medicine*, **2008**, 5, e96	11.6	156
86	Reporting of clinical trials: a review of research funders' guidelines. *Trials*, **2008**, 9, 66	2.8	19
85	Methodological quality of pharmacogenetic studies: issues of concern. *Statistics in Medicine*, **2008**, 27, 6547-69	2.3	59
84	Meta-analysis of diagnostic test studies using individual patient data and aggregate data. *Statistics in Medicine*, **2008**, 27, 6111-36	2.3	63
83	Joint modelling of longitudinal and competing risks data. *Statistics in Medicine*, **2008**, 27, 6426-38	2.3	56
82	Systematic review of the empirical evidence of study publication bias and outcome reporting bias. *PLoS ONE*, **2008**, 3, e3081	3.7	850
81	Importance of competing risks in the analysis of anti-epileptic drug failure. *Trials*, **2007**, 8, 12	2.8	12

80	Multiple treatment comparisons in epilepsy monotherapy trials. *Trials*, **2007**, 8, 34	2.8	81
79	Application and investigation of a bound for outcome reporting bias. *Trials*, **2007**, 8, 9	2.8	21
78	The application of multilevel modelling to dental caries data. *Statistics in Medicine*, **2007**, 26, 4139-49	2.3	25
77	Cervical stitch (cerclage) for preventing pregnancy loss: individual patient data meta-analysis. *BJOG: an International Journal of Obstetrics and Gynaecology*, **2007**, 114, 1460-76	3.7	50
76	Risk factors for complication following ERCP; results of a large-scale, prospective multicenter study. *Endoscopy*, **2007**, 39, 793-801	3.4	297
75	Are we meeting the standards set for endoscopy? Results of a large-scale prospective survey of endoscopic retrograde cholangio-pancreatograph practice. *Gut*, **2007**, 56, 821-9	19.2	152
74	The association between polymorphisms in RLIP76 and drug response in epilepsy. *Pharmacogenomics*, **2007**, 8, 1715-22	2.6	15
73	The influence of competing-risks setting on the choice of hypothesis test for treatment effect. *Biostatistics*, **2007**, 8, 689-94	3.7	29
72	A comparison of methods for fixed effects meta-analysis of individual patient data with time to event outcomes. *Clinical Trials*, **2007**, 4, 621-30	2.2	33
71	Interventions for helping people recognise early signs of recurrence in bipolar disorder. *The Cochrane Library*, **2007**, CD004854	5.2	71
70	Individual patient data meta-analyses compared with meta-analyses based on aggregate data **2007**,		5
69	The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. *Lancet, The*, **2007**, 369, 1000-15	40	708
68	The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. *Lancet, The*, **2007**, 369, 1016-26	40	681
67	Old versus new antiepileptic drugs: the SANAD study Authors' reply. *Lancet, The*, **2007**, 370, 315-316	40	3
66	Clinical factors and ABCB1 polymorphisms in prediction of antiepileptic drug response: a prospective cohort study. *Lancet Neurology, The*, **2006**, 5, 668-76	24.1	63
65	Oxcarbazepine versus phenytoin monotherapy for epilepsy. *Cochrane Database of Systematic Reviews*, **2006**, CD003615		19
64	Efficacy of carbamazepine and valproate as monotherapy for early epilepsy and single seizures. *Neurology*, **2006**, 67, 1872-5	6.5	6
63	HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. *Pharmacogenomics*, **2006**, 7, 813-26	2.8	224

62	Statistical aspects of design and analysis of clinical trials for the prevention of caries. *Caries Research*, **2006**, 40, 360-5	4.2	15
61	Portosystemic shunts versus endoscopic therapy for variceal rebleeding in patients with cirrhosis. *The Cochrane Library*, **2006**, CD000553	5.2	54
60	A meta-analysis of individual patient responses to lamotrigine or carbamazepine monotherapy. *Neurology*, **2006**, 66, 1310-7	6.5	25
59	Lamotrigine versus carbamazepine monotherapy for epilepsy. *Cochrane Database of Systematic Reviews*, **2006**, CD001031		22
58	In a systematic review, infrared ear thermometry for fever diagnosis in children finds poor sensitivity. *Journal of Clinical Epidemiology*, **2006**, 59, 354-7	5.7	58
57	Searching for and use of conference abstracts in health technology assessments: policy and practice. *International Journal of Technology Assessment in Health Care*, **2006**, 22, 283-7	1.8	3
56	Case study of the comparison of data from conference abstracts and full-text articles in health technology assessment of rapidly evolving technologies: does it make a difference?. *International Journal of Technology Assessment in Health Care*, **2006**, 22, 288-94	1.8	8
55	A comparison of multivariable regression models to analyse cost data. *Journal of Evaluation in Clinical Practice*, **2006**, 12, 76-86	2.5	106
54	Comparison of conference abstracts and presentations with full-text articles in the health technology assessments of rapidly evolving technologies. *Health Technology Assessment*, **2006**, 10, iii-iv, ix-145	4.4	31
53	Clinical and Functional Evidence That Drug Transporter Expression Dictates the Response to Imatinib in Chronic Myeloid Leukaemia.. *Blood*, **2006**, 108, 2145-2145	2.2	
52	Individual patient data meta-analysis : Cervical stitch (cerclage) for preventing pregnancy loss in women. *BMC Pregnancy and Childbirth*, **2005**, 5, 5	3.2	2
51	A randomised controlled trial in the north of England examining the effects of skin-to-skin care on breast feeding. *Midwifery*, **2005**, 21, 71-9	2.8	72
50	High prevalence but low impact of data extraction and reporting errors were found in Cochrane systematic reviews. *Journal of Clinical Epidemiology*, **2005**, 58, 741-2	5.7	68
49	An overview of methods and empirical comparison of aggregate data and individual patient data results for investigating heterogeneity in meta-analysis of time-to-event outcomes. *Journal of Evaluation in Clinical Practice*, **2005**, 11, 468-78	2.5	37
48	Topical quinolone vs. antiseptic for treating chronic suppurative otitis media: a randomized controlled trial. *Tropical Medicine and International Health*, **2005**, 10, 190-7	2.3	29
47	Identification and impact of outcome selection bias in meta-analysis. *Statistics in Medicine*, **2005**, 24, 1547-61	2.3	81
46	Investigating heterogeneity in an individual patient data meta-analysis of time to event outcomes. *Statistics in Medicine*, **2005**, 24, 1307-19	2.3	124
45	Outcome selection bias in meta-analysis. *Statistical Methods in Medical Research*, **2005**, 14, 515-24	2.3	140

44	HIV and male circumcision?a systematic review with assessment of the quality of studies. *Lancet Infectious Diseases, The*, **2005**, 5, 165-173	25.5	102
43	Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. *Gut*, **2004**, 53, 1471-8	19.2	232
42	Design and analysis of pilot studies: recommendations for good practice. *Journal of Evaluation in Clinical Practice*, **2004**, 10, 307-12	2.5	1166
41	The value of a pilot study in breast-feeding research. *Midwifery*, **2004**, 20, 188-93	2.8	15
40	Cervical cerclage for prevention of preterm delivery in women with short cervix: randomised controlled trial. *Lancet, The*, **2004**, 363, 1849-53	40	324
39	Cervical cerclage for prevention of preterm delivery in women with short cervix. *Lancet, The*, **2004**, 364, 1935	40	1
38	Interventions for helping people recognise early signs of recurrence in depression. *The Cochrane Library*, **2004**,	5.2	1
37	Coronary artery stents: a rapid systematic review and economic evaluation. *Health Technology Assessment*, **2004**, 8, iii-iv, 1-242	4.4	65
36	Carbamazepine versus phenobarbitone monotherapy for epilepsy. *Cochrane Database of Systematic Reviews*, **2003**, CD001904		20
35	A systematic review of randomised controlled trials evaluating the effect of mother/baby skin-to-skin care on successful breast feeding. *Midwifery*, **2003**, 19, 148-55	2.8	25
34	Investigation of within-study selective reporting in clinical research: follow-up of applications submitted to a local research ethics committee. *Journal of Evaluation in Clinical Practice*, **2002**, 8, 353-9	2.5	78
33	Carbamazepine versus valproate monotherapy for epilepsy: a meta-analysis. *Epilepsia*, **2002**, 43, 505-13	6.4	60
32	Statistical issues in the assessment of the evidence for an interaction between factors in epilepsy trials. *Statistics in Medicine*, **2002**, 21, 2613-22	2.3	9
31	Meta-analysis of method comparison studies. *Statistics in Medicine*, **2002**, 21, 2013-25	2.3	53
30	Aggregate data meta-analysis with time-to-event outcomes. *Statistics in Medicine*, **2002**, 21, 3337-51	2.3	420
29	Carbamazepine versus phenytoin monotherapy for epilepsy. *Cochrane Database of Systematic Reviews*, **2002**, CD001911		20
28	Infrared ear thermometry compared with rectal thermometry in children: a systematic review. *Lancet, The*, **2002**, 360, 603-9	40	219
27	Phenobarbitone versus phenytoin monotherapy for partial onset seizures and generalized onset tonic-clonic seizures. *Cochrane Database of Systematic Reviews*, **2001**, CD002217		14

26	The value of the aggregate data approach in meta-analysis with time-to-event outcomes. *Journal of the Royal Statistical Society Series A: Statistics in Society*, **2001**, 164, 357-370	2.1	27
25	Phenytoin versus valproate monotherapy for partial onset seizures and generalized onset tonic-clonic seizures. *Cochrane Database of Systematic Reviews*, **2001**, CD001769		27
24	Assessing the potential for bias in meta-analysis due to selective reporting of subgroup analyses within studies. *Statistics in Medicine*, **2000**, 19, 3325-36	2.3	94
23	Are systematic reviews taking heterogeneity into account? An analysis from the Infectious Diseases Module of the Cochrane Library. *Journal of Evaluation in Clinical Practice*, **2000**, 6, 231-3	2.5	6
22	Individual patient data meta-analysis of randomized anti-epileptic drug monotherapy trials. *Journal of Evaluation in Clinical Practice*, **2000**, 6, 205-14	2.5	34
21	Statistical review by research ethics committees. *Journal of the Royal Statistical Society Series A: Statistics in Society*, **2000**, 163, 5-13	2.1	18
20	Bias in meta-analysis due to outcome variable selection within studies. *Journal of the Royal Statistical Society Series C: Applied Statistics*, **2000**, 49, 359-370	1.5	109
19	Temperature measured at the axilla compared with rectum in children and young people: systematic review. *BMJ: British Medical Journal*, **2000**, 320, 1174-8		165
18	Carbamazepine versus valproate monotherapy for epilepsy. *The Cochrane Library*, **2000**, CD001030	5.2	50
17	Effects of treatment for intestinal helminth infection on growth and cognitive performance in children: systematic review of randomised trials. *BMJ: British Medical Journal*, **2000**, 320, 1697-701		134
16	National Confidential Enquiry into counselling for genetic disorders by non-geneticists: general recommendations and specific standards for improving care. *BJOG: an International Journal of Obstetrics and Gynaecology*, **1999**, 106, 658-63	3.7	36
15	Confidential inquiry into families with two siblings with cystic fibrosis. *Archives of Disease in Childhood*, **1997**, 77, 501-3	2.2	14
14	Antecedent circumstances surrounding neural tube defect births in 1990-1991. The Steering Committee of the National Confidential Enquiry into Counselling for Genetic Disorders. *BJOG: an International Journal of Obstetrics and Gynaecology*, **1997**, 104, 51-6	3.7	12
13	Observer variation in the assessment of adequacy and neoplasia in cervical cytology. *Acta Cytologica*, **1996**, 40, 226-34	3	12
12	Prenatal genetic services for Down's syndrome: access and provision in 1990-1991. Steering Committee of the National Confidential Enquiry into Counselling for Genetic Disorders. *BJOG: an International Journal of Obstetrics and Gynaecology*, **1996**, 103, 676-83	3.7	10
11	Falling incidence of HIV infection in a cohort of clinic attenders. *Australian Journal of Public Health*, **1993**, 17, 334-8		10
10	Early reocclusion after successful thrombolysis is related to lesion length and roughness. *Coronary Artery Disease*, **1993**, 4, 159-66	1.4	6
9	Effect of coronary stenosis severity on variability of quantitative arteriography, and implications for interventional trials. *American Journal of Cardiology*, **1992**, 69, 806-7	3	12

8	Establishing comprehensive, quantitative criteria for detection of restenosis and remodeling after percutaneous transluminal coronary angioplasty. *American Journal of Cardiology*, **1992**, 69, 77-83	3	12
7	Prognostic importance of quantitative analysis of coronary cineangiograms. *American Journal of Cardiology*, **1992**, 69, 1022-7	3	19
6	Use of routinely collected data in a UK cohort of publicly funded randomised clinical trials. *F1000Research*,9, 323	3.6	2
5	A review of the Cochrane COVID-19 Study Register reveals inconsistency in the choice and measurement of SARS-CoV-2 infection outcomes in prevention trials. *F1000Research*,10, 426	3.6	
4	Representation of published core outcome sets for research in regulatory guidance: protocol. *HRB Open Research*,4, 45	1.2	3
3	A pilot study assessing the similarity between core outcome sets and outcomes included in health technology assessments. *F1000Research*,10, 1084	3.6	
2	Using behavioural science to enhance use of core outcome sets in trials: protocol. *HRB Open Research*,5, 23	1.2	
1	A pilot study assessing the similarity between core outcome sets and outcomes included in health technology assessments. *F1000Research*,10, 1084	3.6	0